Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases. The company uses its proprietary technology to create novel small molecule drug conjugates (SMDCs), and companion imaging agents. The company’s SMDCs actively target receptors that are over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently, and over longer periods of time than would be possible with the untargeted drug alone. Vintafolide in Ovarian Cancer The company’s SMDC, vintafolide (EC145), targets the folate receptor, which is frequently over-expressed in some of the most prevalent and difficult to treat solid tumor indications. The company identifies the presence of the folate receptor in cancer patients by using etarfolatide (EC20), its proprietary companion imaging agent for vintafolide. Collaboration with Merck & Co, Inc. In 2012, the company entered into a worldwide collaboration agreement with Merck Sharp & Dohme Research GmbH, a subsidiary of Merck & Co, Inc., regarding the development and commercialization of vintafolide and the right to use etarfolatide. The agreement grants Merck & Co, Inc. worldwide rights to develop and commercialize vintafolide. The company is responsible for the development, manufacture and commercialization worldwide of etarfolatide. Exclusive License Agreement In 2013, the company entered into a license and commercialization agreement with Nihon Medi-Physic Co., LTD., or NMP, that grants NMP the right to develop and commercialize etarfolatide in Japan for use in connection with vintafolide in Japan. Strategy The company’s strategy is to develop and commercialize SMDCs to treat patients who suffer from various cancers and inflammatory diseases that are not well addressed by available therapies. The main components of its business strategy are to: obtain marketing approval of its SMDC, vintafolide, for use in women with PROC; expand use of vintafolide to other indications; build a pipeline of SMDCs by leveraging technology platform; develop companion imaging agents for each of its therapies; and build commercial capabilities and partner to maximize the value of SMDCs. Patents The company owns 11 issued U.S. patents in whole. Five of these patents relate to vintafolide or etarfolatide compositions of matter. With respect to vintafolide coverage, the company has patents issued in the United States, Japan, Germany, Spain, France, the United Kingdom, and Italy, as well as Australia, China, India, New Zealand, Taiwan and South Africa. Applications are pending in the United States, Japan, Europe, Taiwan, Canada, Israel, Hong Kong, Argentina and Venezuela. History Endocyte, Inc. was founded in 1995. The company was incorporated in the state of Indiana in 1995 and was reincorporated in the state of Delaware in 2001.
(ECYT:Consolidated Issue Listed on NASDAQ Global Select )
3000 Kent Avenue
West Lafayette, IN 47906
|No competitor information is available for ECYT.|
|View Industry Companies|
Sponsored Financial Commentaries
To contact ENDOCYTE INC, please visit www.endocyte.com. Company data is provided by Capital IQ. Please use this form to report any data issues.